vs
Side-by-side financial comparison of Elevance Health (ELV) and TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM). Click either name above to swap in a different company.
Elevance Health is the larger business by last-quarter revenue ($49.7B vs $35.5B, roughly 1.4× TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD). TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD runs the higher net margin — 50.5% vs 1.1%, a 49.4% gap on every dollar of revenue.
Elevance Health, Inc. is an American health insurance company. Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon.
Taiwan Semiconductor Manufacturing Company (TSMC) is the world's largest dedicated independent semiconductor foundry, headquartered in Hsinchu, Taiwan. It manufactures advanced logic chips on contract for fabless customers including Apple, NVIDIA, AMD, Qualcomm, and Broadcom, and leads the industry in leading-edge process nodes (3nm/5nm/7nm).
ELV vs TSM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $49.7B | $35.5B |
| Net Profit | $547.0M | $17.9B |
| Gross Margin | 88.9% | 66.2% |
| Operating Margin | 0.6% | 58.0% |
| Net Margin | 1.1% | 50.5% |
| Revenue YoY | 1.8% | — |
| Net Profit YoY | -74.9% | — |
| EPS (diluted) | $2.56 | $111.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $49.7B | $35.5B | ||
| Q4 25 | $49.7B | $32.7B | ||
| Q3 25 | $50.7B | $30.7B | ||
| Q2 25 | $49.8B | $28.9B | ||
| Q1 25 | $48.9B | $26.0B | ||
| Q4 24 | $45.4B | $88.3B | ||
| Q3 24 | $45.1B | — | ||
| Q2 24 | $43.9B | — |
| Q1 26 | $547.0M | $17.9B | ||
| Q4 25 | $547.0M | $15.8B | ||
| Q3 25 | $1.2B | $14.0B | ||
| Q2 25 | $1.7B | $12.3B | ||
| Q1 25 | $2.2B | $11.2B | ||
| Q4 24 | $418.0M | $35.3B | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $2.3B | — |
| Q1 26 | 88.9% | 66.2% | ||
| Q4 25 | 88.9% | 62.3% | ||
| Q3 25 | 89.4% | 59.5% | ||
| Q2 25 | 89.4% | 58.6% | ||
| Q1 25 | 89.8% | 58.8% | ||
| Q4 24 | 86.8% | 56.1% | ||
| Q3 24 | 88.7% | — | ||
| Q2 24 | 89.0% | — |
| Q1 26 | 0.6% | 58.0% | ||
| Q4 25 | 0.6% | 53.9% | ||
| Q3 25 | 2.6% | 50.6% | ||
| Q2 25 | 4.9% | 49.6% | ||
| Q1 25 | 6.5% | 48.5% | ||
| Q4 24 | 1.5% | 45.7% | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 6.3% | — |
| Q1 26 | 1.1% | 50.5% | ||
| Q4 25 | 1.1% | 48.3% | ||
| Q3 25 | 2.3% | 45.7% | ||
| Q2 25 | 3.5% | 42.7% | ||
| Q1 25 | 4.5% | 43.1% | ||
| Q4 24 | 0.9% | 40.0% | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 5.2% | — |
| Q1 26 | $2.56 | $111.55 | ||
| Q4 25 | $2.56 | $98.45 | ||
| Q3 25 | $5.32 | $87.20 | ||
| Q2 25 | $7.72 | $76.80 | ||
| Q1 25 | $9.61 | $69.70 | ||
| Q4 24 | $1.88 | $1.36 | ||
| Q3 24 | $4.36 | — | ||
| Q2 24 | $9.85 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.5B | — |
| Total DebtLower is stronger | $31.9B | — |
| Stockholders' EquityBook value | $43.9B | — |
| Total Assets | $121.5B | — |
| Debt / EquityLower = less leverage | 0.73× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $9.5B | — | ||
| Q4 25 | $9.5B | — | ||
| Q3 25 | $8.7B | — | ||
| Q2 25 | $8.6B | — | ||
| Q1 25 | $7.5B | — | ||
| Q4 24 | $8.3B | $64.9B | ||
| Q3 24 | $7.9B | — | ||
| Q2 24 | $6.5B | — |
| Q1 26 | $31.9B | — | ||
| Q4 25 | $31.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $30.9B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $43.9B | — | ||
| Q4 25 | $43.9B | — | ||
| Q3 25 | $44.0B | — | ||
| Q2 25 | $43.7B | — | ||
| Q1 25 | $42.5B | — | ||
| Q4 24 | $41.3B | $130.5B | ||
| Q3 24 | $43.8B | — | ||
| Q2 24 | $42.2B | — |
| Q1 26 | $121.5B | — | ||
| Q4 25 | $121.5B | — | ||
| Q3 25 | $122.7B | — | ||
| Q2 25 | $121.9B | — | ||
| Q1 25 | $119.7B | — | ||
| Q4 24 | $116.9B | $204.1B | ||
| Q3 24 | $116.5B | — | ||
| Q2 24 | $113.0B | — |
| Q1 26 | 0.73× | — | ||
| Q4 25 | 0.73× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
